Bi Asset Management Fondsmaeglerselskab A Seagen Inc. Transaction History

Bi Asset Management Fondsmaeglerselskab A

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $85,604 - $96,623	-447 Reduced 15.88%	2,367 $502,000
Q2 2023 Aug 03, 2023	BUY	$187.64 - $206.25 $46,534 - $51,150	248 Added 9.66%	2,814 $542,000
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $71,067 - $113,115	-557 Reduced 17.84%	2,566 $520,000
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $144,130 - $170,900	1,228 Added 64.8%	3,123 $401,000
Q3 2022 Nov 07, 2022	SELL	$135.27 - $180.11 $153,531 - $204,424	-1,135 Reduced 37.46%	1,895 $259,000
Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $76,167 - $125,531	700 Added 30.04%	3,030 $536,000
Q1 2022 May 11, 2022	BUY	$119.61 - $157.85 $278,691 - $367,790	2,330 New	2,330 $336,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $2.97 Million - $4.12 Million	-21,596 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $3.56 Million - $4.58 Million	21,596 New	21,596 $3.78 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.